A Phase 2b Study of Inhaled RVT-1601 for the Treatment of Persistent Cough in IPF
Status:
Terminated
Trial end date:
2020-06-05
Target enrollment:
Participant gender:
Summary
Idiopathic pulmonary fibrosis (IPF) is a rare, progressive life-threatening disease that is
characterized by exertional dyspnea and persistent dry cough.
Cough in IPF is both a presenting and a complicating clinical feature, which affects
approximately three quarters of IPF cases. It is often a debilitating symptom that adversely
affects quality of life (QoL) and is usually refractory to medical therapy.
Inhaled RVT-1601 (formerly, PA101B), a new inhalation formulation of cromolyn sodium
delivered via the eFlow® Closed System (CS) nebulizer, is being evaluated in this Phase 2b
study for the treatment of persistent cough in patients with IPF.